Company news
Diagnostear Technologies, Inc. (CSE:DTR) news
Diagnostear Technologies, Inc. news releases on 6ix. Latest, Sep 10, 2026: DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating…
Press releases & updates
DiagnosTear Announces Positive Final Results from Clinical Study Demonstrating Strong Diagnostic Performance of TeaRx(TM) Red Eye for Detecting Total Tear IgE as a Biomarker for Allergic conjunctivitis
September 10, 2026
DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test
September 3, 2026
DiagnosTear Technologies Inc. Announces Private Placement of Units
August 31, 2026
DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx(TM) Red Eye and Quantitative ELISA Testing
July 9, 2026
DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx(TM) Clinical Study in Current Eye Research Journal
June 5, 2026
RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
May 13, 2026
DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
May 12, 2026
DiagnosTear Technologies Inc. Announces Results of AGM
May 7, 2026
DiagnosTear Technologies Inc. Announces Warrant Extension
May 4, 2026
DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting
April 21, 2026
DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye
February 26, 2026
DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical
February 20, 2026
DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India
January 22, 2026
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
January 15, 2026
DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count
December 17, 2025
DiagnosTear Technologies Inc. - Confirmation of No Material Change
December 9, 2025
DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test
December 2, 2025
DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test
November 26, 2025
DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units
November 18, 2025
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
October 24, 2025
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
October 22, 2025
DiagnosTear Technologies Inc. Grants Stock Options
February 5, 2025
DiagnosTear Technologies Inc. Commenced Trading on the Canadian Securities Exchange
December 10, 2024